AMARIN CORP PLC\UK Contract with Customer, Performance Obligation Satisfied in Previous Period
AMARIN CORP PLC\UK (AMRN) reported Contract with Customer, Performance Obligation Satisfied in Previous Period of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes
us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod · last filed 2026-03-02
- AMARIN CORP PLC\UK contract with customer, performance obligation satisfied in previous period for the quarter ending 2025-12-31 was $0.00.
- AMARIN CORP PLC\UK contract with customer, performance obligation satisfied in previous period for the quarter ending 2025-09-30 was $0.00.
- AMARIN CORP PLC\UK contract with customer, performance obligation satisfied in previous period for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- AMARIN CORP PLC\UK contract with customer, performance obligation satisfied in previous period for the quarter ending 2024-09-30 was $0.00.
- AMARIN CORP PLC\UK contract with customer, performance obligation satisfied in previous period for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- AMARIN CORP PLC\UK contract with customer, performance obligation satisfied in previous period for fiscal 2024 was $3.67M, a 77.32% decline from fiscal 2023.
- AMARIN CORP PLC\UK contract with customer, performance obligation satisfied in previous period for fiscal 2023 was $16.18M, a 809000.00% increase from fiscal 2022.
- AMARIN CORP PLC\UK contract with customer, performance obligation satisfied in previous period for fiscal 2022 was $2.00K, a 95.65% decline from fiscal 2021.
| Period end | Contract with Customer, Performance Obligation Satisfied in Previous Period 3 month | Contract with Customer, Performance Obligation Satisfied in Previous Period 6 month | Contract with Customer, Performance Obligation Satisfied in Previous Period 9 month | Contract with Customer, Performance Obligation Satisfied in Previous Period 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 10-K · filed 2026-03-02 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $0.00 10-Q · filed 2025-10-29 | ||
| 2025-06-30 | $0.00 10-Q · filed 2025-07-30 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $3.67M 10-K · filed 2026-03-02 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $3.67M 10-Q · filed 2025-10-29 | ||
| 2024-06-30 | $3.67M 10-Q · filed 2025-07-30 | |||
| 2023-12-31 | $14.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $14.46M derived: sum of 2 quarters · filed 2026-03-02 | $16.18M 10-K · filed 2026-03-02 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $1.72M 10-Q · filed 2024-10-30 | ||
| 2023-06-30 | $1.72M 10-Q · filed 2024-07-31 | |||
| 2022-12-31 | $2.00K 10-K · filed 2024-02-29 | |||
| 2021-12-31 | $13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $24.00K derived: sum of 2 quarters · filed 2023-03-01 | $46.00K 10-K · filed 2023-03-01 | |
| 2021-09-30 | $11.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $33.00K 10-Q · filed 2022-10-27 | ||
| 2021-06-30 | $22.00K 10-Q · filed 2021-08-05 | |||
| 2020-12-31 | $165.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $165.00K derived: sum of 2 quarters · filed 2022-03-01 | $165.00K derived: sum of 3 quarters · filed 2022-03-01 | $1.26M 10-K · filed 2022-03-01 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $0.00 derived: sum of 2 quarters · filed 2021-11-03 | $1.10M 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $1.10M 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $1.10M 10-Q · filed 2021-04-29 | |||
| 2019-12-31 | $299.00K 10-K · filed 2021-02-25 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $193.00K 10-K · filed 2020-02-25 | ||
| 2018-09-30 | $193.00K 10-Q · filed 2019-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |